Clinical Trials Browser

Approved for marketing × Ovarian Diseases × Clear all

NCT03079687 2017-10-25

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Approved for marketing

Carcinoma, Ovarian Epithelial, Neoplasms, Ovarian Diseases, Ovarian Neoplasms